Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;25(11):1406-1418.
doi: 10.2174/0113892010254221231006100659.

A Glance on Nanovaccine: A Potential Approach for Disease Prevention

Akash Garg  1 , Rutvi Agrawal  1 , Himansu Chopra  1 , Talever Singh  1 , Ramkumar Chaudhary  1 , Abhishek Tankara  1
Affiliations
Review

A Glance on Nanovaccine: A Potential Approach for Disease Prevention

Akash Garg et al. Curr Pharm Biotechnol. 2024.

Abstract

There are several vaccines available for preventing various bacterial and viral infections, but still, there are many challenges that require the development of noninvasive, more efficient, and active vaccines. The advancement in biotechnological tools has provided safer antigens, such as nucleic acids, proteins etc., but due to their lower immunogenic property, adjuvants of stronger immune response are required. Nanovaccines are effective vaccines when compared with conventional vaccines as they can induce both Humoral and cell-mediated immune responses and also provide longer immunogenic memory. The nanocarriers used in vaccines act as adjuvant. They provide site-specific delivery of antigens and can be used in conjugation with immunostimulatory molecules for enhancing adjuvant therapy. The nanovaccines avoid degrading cell pathways and provide effective absorption into blood vessels. The higher potential of nanovaccines to treat various diseases, such as acquired immuno deficiency syndrome, cancer, tuberculosis, malaria and many others, along with their immunological mechanisms and different types, have been discussed in the review.

Keywords: Vaccine; cell-mediated.; humoral; immune response; infectious diseases; nanovaccine.

PubMed Disclaimer

References

    1. Sekhon B.; Sekhon B.; Saluja V.; Nanovaccines-An overview. Inter J Pharma Frontier Res 2011,1,101-109
    1. Griffin J.; A strategic approach to vaccine development: Animal models, monitoring vaccine efficacy, formulation and delivery. Adv Drug Deliv Rev 2002,54(6),851-861 - DOI - PubMed
    1. Riedel S.; Edward Jenner and the history of smallpox and vaccination. Proc Bayl Univ Med Cent 2005,18(1),21-25 - DOI - PubMed
    1. Kaufmann S.H.E.; Juliana McElrath M.; Lewis D.J.M.; Del Giudice G.; Challenges and responses in human vaccine development. Curr Opin Immunol 2014,28,18-26 - DOI - PubMed
    1. Barouch D.H.; Challenges in the development of an HIV-1 vaccine. Nature 2008,455(7213),613-619 - DOI - PubMed